Cardiac Dimensions has announced the completion of a $43 million round of equity financing.
Cardiac Dimensions, based in Kirkland, Wash., develops minimally invasive treatment modalities to address heart failure and related cardiovascular conditions.
The funding round included investments from Life Sciences Partners, Aperture Venture Partners, Lumira Capital, M.H. Carnegie & Co. and Arboretum Ventures.
In a news release, Cardiac Dimensions indicated the proceeds of the round will be used to support the company's REDUCE FMR clinical trial. REDUCE FMR is blinded, randomized clinical trial of a percutaneous mitral repair device in patients with functional mitral regurgitation (FMR).
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.